Status: Recruiting
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Participants needed: 45
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Alexion Pharmaceuticals, Inc.Updated: Jun 18, 2026Locations: 55
Eligibility criteria
Kidney transplant received ≥ 6 months [+8]
TCMR, according to the Banff grade ≥ 1 [+8]